NCT00659711

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University at Buffalo · Academic / Other
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values. Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Januvia (Sitagliptin) 100 mg	The first group will be started on 100 mg sitagliptin daily for 12 weeks
DRUG	Placebo	will be placed on a placebo for 12 weeks.

Timeline

• Start date: 2008-03-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2008-04-16
• Last updated: 2022-07-21
• Results posted: 2022-07-21

Locations

1 site across 1 country: United States